Paralel Advisors LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 23.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 6,565 shares of the medical research company’s stock after selling 2,020 shares during the period. Paralel Advisors LLC’s holdings in Amgen were worth $2,377,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Anfield Capital Management LLC lifted its position in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its position in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Tower View Wealth Management LLC increased its position in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC raised its stake in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new position in shares of Amgen in the fourth quarter worth about $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Amgen
In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Research Report on Amgen
Amgen Price Performance
Shares of AMGN stock opened at $433.73 on Friday. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $443.20. The stock has a market cap of $234.49 billion, a PE ratio of 26.96, a PEG ratio of 4.09 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm’s 50 day moving average price is $377.35 and its two-hundred day moving average price is $361.40.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the prior year, the business posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts forecast that Amgen Inc. will post 22.89 EPS for the current year.
Amgen Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio is presently 62.65%.
Trending Headlines about Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Unusually heavy call-option activity points to increased bullish positioning. Investors purchased 79,035 call options, roughly 931% above typical volume, although options activity is speculative and does not guarantee future gains.
- Positive Sentiment: Argus raised its price target from $375 to $460 and upgraded Amgen to “Buy,” adding to the series of favorable analyst views. Argus price target report
- Positive Sentiment: Mizuho and Cantor Fitzgerald analysts also projected further appreciation for Amgen, reinforcing the bullish sentiment around the company’s earnings performance and pipeline. Mizuho Amgen forecast Cantor Fitzgerald Amgen outlook
- Positive Sentiment: Amgen has outperformed several major drugmakers in 2026, attracting investor interest as markets favor profitable pharmaceutical companies even without an obesity-drug franchise. Drugmaker stock performance comparison
- Neutral Sentiment: Biotech ETFs are benefiting from innovation, obesity-drug demand and merger activity, creating a favorable sector backdrop, though the article does not identify a specific new catalyst for Amgen. Biotech ETF growth article
- Negative Sentiment: Industry caution around obesity-drug development is a risk: investors are penalizing undifferentiated programs, and Amgen has reportedly trimmed some early-stage efforts. Obesity drug investment outlook
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Articles
- Five stocks we like better than Amgen
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
